Recombinant Proteins
Growth Factors and Cytokines
CD Antigens
Affinity Ligands
Other Proteins
Transfection Reagents
For Cell Lines
For Primary Cells
ALK-1 / ACVRL1 (Activin Receptor-like Kinase 1), Human
Catalog Number: EZC-AL1-H1
Synonym: ACVRL1, ACVRL-1, ACVRLK1, ALK-1, ALK1, HHT, HHT2, HHT-2, ORW2, ORW-2, SKR3, SKR-3, TSR-I, TSR-?
Source: Recombinant activin receptor-like kinase 1 (rhACVRL1 or rhALK1), Met 1- Gln118(Accession # NP_000011.2) was expressed in HEK 293
Molecular Characterization: rhALK1, a 108 amino acids protein with polyhistidine tag at C-terminus, and has a calculated MW of 12.3 kDa. The predicted N-terminal is Asp22. DTT-reduced protein migrates as 26 kDa protein due to glycosylation.
Purity: >97% purity as determined by SDS-PAGE of reduced rhALK1.
Endotoxin: Less than 0.01 ng endotoxin per g rhALK1.
Formulation: Bulk protein in a 0.22 m filtered solution of PBS, pH 7.4 and delivered as liquid formulation or lyophilized powder. Normally 5-8% trehalose and mannitol are added as protectants before lyophilization.
Storage: Store at -20? in lyophilized state after receipt. For long term storage, upon reconstitution rhALK1 should be aliquot and store at -20? or -80?. Avoid repeated freeze-thaw cycles.
Background: Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene(1)( 2). ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic(3).Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells(4).
      Research Use Only. Not for use in diagnostic or therapeutic procedures.
Purchase This Product
  Size Price Number
  100 g $364.00
  1 mg $2,520.00
(1) Ten Dijke P, Ichijo H, et al. (Oct 1993). Oncogene 8 (10): 287987 (2) Johnson DW, Berg JN, et al.(Jul 1996). Nat Genet 13 (2): 18995 (3) Lawlor MW, Read BP, et al. (Feb.2011). Am J Pathol. 178(2):784-93 (4) Mitchell D,et al.(Feb. 2010). Mol Cancer Ther.. 9(2):379-88
EZ Biosystems LLC. All Right Reserved